Literature DB >> 2429101

Effects of amiodarone and desethylamiodarone on rabbit myocardial beta-adrenoceptors and serum thyroid hormones--absence of relationship to serum and myocardial drug concentrations.

N Venkatesh, J F Padbury, B N Singh.   

Abstract

The antiadrenergic actions of amiodarone (Am) are well known but its effect and that of its metabolite, desethylamiodarone (DAm), on beta-receptor density (Bmax) and affinity (KD) are poorly defined. Thus, the acute and chronic effects of Am and DAm on myocardial beta-receptors in rabbits were determined relative to changes in thyroid hormones and serum and tissue drug concentrations. Bmax and KD were measured by radio-ligand binding, thyroid hormones by RIA, and drug levels by HPLC. Compared with controls, intravenous Am (20 mg/kg) reduced Bmax by 23% (p less than 0.05) and DAm (20 mg/kg) by 32% (p less than 0.05). After 3 weeks of chronic drug, the corresponding value for Am was 24% (p less than 0.05) versus 45% (p less than 0.05) for DAm. The effect of DAm was significantly greater (p less than 0.05) than that of Am, being comparable to that of Am (-44%) after 6 weeks. In the case of Am, doubling the dose (and myocardial level) led to no further decrease in Bmax. DAm also reduced Bmax more following chronic treatment than after acute administration (-45 versus -32%), a difference of borderline significance. Following 3 weeks of p.o. Am, T3 decreased 3% (NS) and reverse T3 (rT3) increased 90% (p less than 0.05); after 6 weeks, the corresponding values were 25% (p less than 0.05) and 181% (p less than 0.01). After 1 week of p.o. DAm, T3 did not change but rT3 increased by 34% (p less than 0.05); after 3 weeks the corresponding values were 21% (p less than 0.01) and 64% (p less than 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2429101     DOI: 10.1097/00005344-198609000-00016

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  5 in total

Review 1.  Recent advances in understanding the pharmacology of amiodarone.

Authors:  S Nattel; M Talajic
Journal:  Drugs       Date:  1988-08       Impact factor: 9.546

Review 2.  Amiodarone in long term prophylaxis.

Authors:  D Katritsis; A J Camm
Journal:  Drugs       Date:  1991       Impact factor: 9.546

3.  Regulation of A1 adenosine receptors by amiodarone and electrical stimulation in rat myocardial cells in vitro.

Authors:  D El-Ani; K A Jacobson; A Shainberg
Journal:  Biochem Pharmacol       Date:  1997-09-01       Impact factor: 5.858

4.  Interaction of the antiarrhythmic agents SR 33589 and amiodarone with the beta-adrenoceptor and adenylate cyclase in rat heart.

Authors:  P Chatelain; L Meysmans; J R Mattéazzi; P Beaufort; M Clinet
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

5.  High-dosage continuous amiodarone therapy to treat new-onset supraventricular tachyarrhythmias in surgical intensive care patients: an observational study.

Authors:  Andreas J Mayr; Martin W Dünser; Nicole Ritsch; Werner Pajk; Barbara Friesenecker; Hans Knotzer; Hanno Ulmer; Volker Wenzel; Walter R Hasibeder
Journal:  Wien Klin Wochenschr       Date:  2004-05-31       Impact factor: 1.704

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.